« Back
Home /
PD184352 (CI-1040)

PD184352 (CI-1040)

Manufacturer	Selleckchem
Category	Oncology Neuroscience Neural Lineage Markers Neuroinflammation Molecular Targets for Neuroscience Targets for Rodent Neurosciences Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Colorectal Cancer Breast Cancer Heart & Blood Cancer Pancreatic Cancer Uterine, Ovarian & Cervical Cancer Astrocyte Markers
Type	Inhibitors
Specific against	other
Amount	10 mM/1 ml
Item no.	S1020-10mM
CASRN	212631-79-3
eClass 6.1	30220300
eClass 9.0	32160605
Available
Alias	MEK1, MEK2;MEK
Administration	Orally twice daily via p.o.
Animal Models	PTC cells in athymic mice
Cell lines	Colon 26 carcinoma cells
Chemical Name	2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3, 4-difluorobenzamide
Clinical Trials	Currently under Phase II in breast cancer, colorectal cancer, lung cancer, and pancreatic cancer.
Concentrations	0.1-10 uM
Description	CI-1040 (PD 184352) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM.
Dosages	150 mg/kg
Features	First MEK inhibitor to begin clinical development.
Formulation	Cremophor EL–95% ethanol (50:50) and dilutes with water
IC50	17 nM, 17 nM, 17 nM, 17 nM, 17 nM, 17 nM
In vitro	CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 uM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10uM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 uM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]
In vivo	Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040, and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]
Incubation Time	24 hours
Kinase Assay	[2], MEK1 Assay, MAP kinase is activated after phosphorylation by MEK, the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50uL of 50 mM Tris, pH 7.4/10 mM MgCl 2 /2 mM EGTA/10 uM [gamma-32P]ATP containing 10 ug of GST-MEK1, 0.5 ug of GST-MAPK, and 40 ug of MBP. After incubation at 30C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Method	Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 g/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 C. After filtration, samples are analyzed by flow cytometry.
Molecular Weight (MW)	478, 67
Picture ChemicalStructure Description	CI-1040 (PD184352) Chemical Structure
Picture Description 1	Data from [SCIENCE, 2011, 331, 912-916], CI-1040 (PD184352)purchased from Selleck, The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.
Picture Description 2	Data from [Neoplasia, 2011, 13, 154166], CI-1040 (PD184352)purchased from Selleck, Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-M concentration.
Solubility (25C)	DMSO 96 mg/mL, Water <1 mg/mL, Ethanol 14 mg/mL
Storage	2 years -20CPowder, 2 weeks4Cin DMSO, 2 months-80Cin DMSO

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10 mM/1 ml

available

Delivery expected until 7/19/2024

Express Delivery: Save 2 days

Compare

Add to wishlist

Recommend by mail